Key result
Mortality for older U.S. adults with Alzheimer's and hypertension increases ~314% between 1999 and 2023.
Why the study?
The national mortality burden of coexisting Alzheimer's disease and hypertension across demographic and geographic groups remains poorly defined.
Observational (n=504,360)
Yes
Answers are grounded in this paper and cite their sources.
Mortality associated with coexisting Alzheimer's disease and hypertension in U.S. older adults has quadrupled over the past two decades, with the highest burden observed in women and non-Hispanic African American adults.
BackgroundHypertension (HTN) is a major modifiable risk factor associated with cognitive decline including Alzheimer's disease (AD), which continues to be the leading cause of dementia and death in the United States (U.S.). However, the national mortality burden of coexisting AD and HTN across demographic and geographic groups remains poorly defined.ObjectiveWe aimed to study these trends to provide insights for better prevention, management, and policy planning.MethodsA retrospective analysis was conducted using the CDC WONDER Multiple Cause-of-Death database (1999-2023), focusing on adults aged ≥65 years with AD and HTN. Temporal trends were assessed using Joinpoint regression to estimate annual percent changes. Mortality patterns were examined by sex, race, region, urban-rural status, state, and place of death.ResultsBetween 1999 and 2023, 504,360 deaths among U.S. adults aged ≥65 years listed both AD and HTN on death certificates, with age-adjusted mortality rates rising from 14.5 to 60.0 per 100,000. Women consistently experienced higher mortality than men (67.5 versus 48.1 per 100,000 in 2023). Non-Hispanic African American adults had the greatest overall burden (57.1) among races. Geographically, mortality was highest in non-metropolitan areas (48.7) and the West region (52.6), More than half of all deaths occurred in nursing homes or long-term care facilities.ConclusionsMortality for coexisting AD and HTN has quadrupled in the U.S. over the past two decades with substantial variations across groups, highlighting the substantial burden of deaths where AD and HTN coexist and the importance of effective HTN control and dementia care across the lifespan.
No takes yet. Share an insight, caveat, or question.
Rashid et al. (2026) conducted an observational in Coexisting Alzheimer's disease and hypertension (n=504,360). Coexisting Alzheimer's disease and hypertension was evaluated on Age-adjusted mortality rate per 100,000. Age-adjusted mortality rates for U.S. adults aged ≥65 years with coexisting Alzheimer's disease and hypertension quadrupled from 14.5 to 60.0 per 100,000 between 1999 and 2023.
Synapse has enriched 10 related papers. Consider them for comparative context: